MX2014000113A - Compuestos para tratar neuropatias perifericas y otros desordenes neurodegenerativos. - Google Patents
Compuestos para tratar neuropatias perifericas y otros desordenes neurodegenerativos.Info
- Publication number
- MX2014000113A MX2014000113A MX2014000113A MX2014000113A MX2014000113A MX 2014000113 A MX2014000113 A MX 2014000113A MX 2014000113 A MX2014000113 A MX 2014000113A MX 2014000113 A MX2014000113 A MX 2014000113A MX 2014000113 A MX2014000113 A MX 2014000113A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- neurodegenerative disorders
- peripheral neuropathies
- treating peripheral
- disease
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
- 208000033808 peripheral neuropathy Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000027232 peripheral nervous system disease Diseases 0.000 title 1
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 abstract 2
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 abstract 2
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 108091006112 ATPases Proteins 0.000 abstract 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000005264 motor neuron disease Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
Abstract
Se proporciona compuesto y métodos para el tratamiento o la prevención de una enfermedad, trastorno o afección neurodegenerativa asociada con la actividad general de hsp90 pero no con la actividad de ATPasa de hsp90, incluyendo neuropatía, tal como neuropatía periférica causada por quimioterapia o diabetes, trastornos del sistema nervioso central, tal como enfermedad de Alzheimer y enfermedad de parkinson, y enfermedades neuromotoras tales como esclerosis lateral amiotrófica (ALS), en un sujeto.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161499242P | 2011-06-21 | 2011-06-21 | |
| US201161499921P | 2011-06-22 | 2011-06-22 | |
| PCT/US2012/043475 WO2012177831A2 (en) | 2011-06-21 | 2012-06-21 | Compounds for treating peripheral neuropathies and other neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014000113A true MX2014000113A (es) | 2015-04-13 |
Family
ID=47423197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014000113A MX2014000113A (es) | 2011-06-21 | 2012-06-21 | Compuestos para tratar neuropatias perifericas y otros desordenes neurodegenerativos. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9527817B2 (es) |
| EP (1) | EP2723339A4 (es) |
| CN (1) | CN103702669A (es) |
| AU (1) | AU2012272924A1 (es) |
| CA (1) | CA2840003A1 (es) |
| MX (1) | MX2014000113A (es) |
| WO (1) | WO2012177831A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104569398B (zh) * | 2013-10-22 | 2016-06-22 | 北京勤邦生物技术有限公司 | 检测乙氧基喹啉的酶联免疫试剂盒及其应用 |
| EP3377476B1 (en) * | 2015-11-16 | 2022-10-26 | PTC Therapeutics, Inc. | Hydrogen isotope-enriched analogues of 1,2,4-oxadiazole benzoic acid compounds, compositions and uses thereof |
| US11519893B2 (en) | 2017-07-06 | 2022-12-06 | Ken-ichi YAMADA | Therapeutic drug for lipid-peroxidation-induced diseases and screening method for therapeutic drugs for lipid-peroxidation-induced diseases |
| CN107779436A (zh) * | 2017-10-27 | 2018-03-09 | 南京中医药大学 | 化疗所致周围神经病变细胞模型构建及其检测方法 |
| EP3897670A4 (en) * | 2018-12-19 | 2022-09-07 | Disarm Therapeutics, Inc. | MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS |
| US11234947B2 (en) * | 2020-06-30 | 2022-02-01 | Imperial College Innovations Limited | Treatment of peripheral neuropathy induced by cancer chemotherapy |
| WO2022265960A1 (en) * | 2021-06-13 | 2022-12-22 | Daya Drug Discoveries, Inc. | Prevention and treatment of neuronal damage with pyridoindolobenz[b, d] azepine compositions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3952023A (en) | 1972-12-16 | 1976-04-20 | Nippon Oil Company Ltd. | Method for preparing adduct of butadiene polymer or copolymer and α, β-ethylenically unsaturated dicarboxylic acid compound |
| US4196113A (en) * | 1973-11-01 | 1980-04-01 | Nippon Oil Co., Ltd. | Water-soluble coating composition |
| US6746678B1 (en) | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
| US6335157B1 (en) * | 1999-05-07 | 2002-01-01 | The European Molecular Biology Laboratory | Method based on localization of Hsp90 to the centrosome |
| US20070078144A1 (en) | 2003-01-29 | 2007-04-05 | Stockwell Brent R | Agents for treating neurodegenerative diseases |
| ATE523208T1 (de) * | 2003-12-22 | 2011-09-15 | Novartis Ag | Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie |
| WO2007087716A1 (en) * | 2006-02-01 | 2007-08-09 | Aegera Therapeutics Inc. | Assay for identifying inhibitors of neuronal apoptotic pathways |
| US7960353B2 (en) * | 2007-05-10 | 2011-06-14 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| JP5582783B2 (ja) * | 2007-12-28 | 2014-09-03 | 武田薬品工業株式会社 | 細胞保護剤のスクリーニング方法 |
-
2012
- 2012-06-21 MX MX2014000113A patent/MX2014000113A/es unknown
- 2012-06-21 AU AU2012272924A patent/AU2012272924A1/en not_active Abandoned
- 2012-06-21 CN CN201280036503.3A patent/CN103702669A/zh active Pending
- 2012-06-21 WO PCT/US2012/043475 patent/WO2012177831A2/en not_active Ceased
- 2012-06-21 CA CA2840003A patent/CA2840003A1/en not_active Abandoned
- 2012-06-21 US US14/127,326 patent/US9527817B2/en active Active
- 2012-06-21 EP EP12802536.8A patent/EP2723339A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20140303203A1 (en) | 2014-10-09 |
| EP2723339A2 (en) | 2014-04-30 |
| WO2012177831A2 (en) | 2012-12-27 |
| CA2840003A1 (en) | 2012-12-27 |
| EP2723339A4 (en) | 2015-02-25 |
| AU2012272924A1 (en) | 2014-01-16 |
| WO2012177831A3 (en) | 2013-04-11 |
| US9527817B2 (en) | 2016-12-27 |
| CN103702669A (zh) | 2014-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014000113A (es) | Compuestos para tratar neuropatias perifericas y otros desordenes neurodegenerativos. | |
| Wolf et al. | APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease | |
| Eyles et al. | Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease | |
| PH12013501490A1 (en) | Methods for diagnosing and treating eye-length related disorders | |
| MX2022012524A (es) | Adeno-asociado para administracion terapeutica al sistema nervioso central. | |
| MX354662B (es) | Anticuerpos fosfoespecificos que reconocen la tau. | |
| MY164376A (en) | Phosphospecific antibodies recognizing tau | |
| MX2008009947A (es) | Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos. | |
| WO2014037416A3 (en) | Compositions for treating parkinson's disease | |
| WO2014150817A3 (en) | Method and system to predict response to treatments for mental disorders | |
| AU2012205878A8 (en) | miRNA for treating diseases and conditions associated with neo-angiogenesis | |
| WO2013033037A3 (en) | Novel antiprion compounds | |
| MX2015005174A (es) | Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo. | |
| EA033420B1 (ru) | Производные индолин-2-она или пирролопиридин-2-она, обладающие антипсихотической активностью | |
| MX392158B (es) | Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). | |
| CA2851761C (en) | Method of diagnosis, prognostic or treatment of neurodegenerative diseases | |
| IN2014DN09826A (es) | ||
| EP2542085A4 (en) | COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER | |
| SA515360200B1 (ar) | محاكيات عامل نمو خلية كبدية كعوامل علاجية | |
| MX2014014066A (es) | Compuestos de cromano. | |
| WO2008057609A8 (en) | Methods of treating neuronal disorders using mntf peptides and analogs thereof | |
| JO3483B1 (ar) | 4-هيدروكسي -2- مثيل -5- (بروبان-2-يليدين) هكس - 3- ين حلقي كربالدهيد للوقاية من ومعالجة مرض معرفي أو تنكسي عصبي أو عصبي | |
| RU2014153894A (ru) | Способ предупреждения неврологических заболеваний | |
| WO2012103282A3 (en) | Methods and compositions for treating alzheimer's disease | |
| ATE382101T1 (de) | Einen transkriptionsfaktor kodierendes humanes prädispositionsgen für autismus sowie dessen verwendungen |